Attached files

file filename
EX-10.8 - EXHIBIT 10.8 - Salarius Pharmaceuticals, Inc.flks20151231ex-108.htm
EX-31.1 - EXHIBIT 31.1 - Salarius Pharmaceuticals, Inc.flks20151231ex-311.htm
EX-32.1 - EXHIBIT 32.1 - Salarius Pharmaceuticals, Inc.flks20151231ex321.htm
EX-10.18 - EXHIBIT 10.18 - Salarius Pharmaceuticals, Inc.flks20151231ex-1018.htm
EX-32.2 - EXHIBIT 32.2 - Salarius Pharmaceuticals, Inc.flks20151231ex-322.htm
EX-10.9 - EXHIBIT 10.9 - Salarius Pharmaceuticals, Inc.flks20151231ex-109.htm
EX-31.2 - EXHIBIT 31.2 - Salarius Pharmaceuticals, Inc.flks20151231ex-312.htm
EX-10.22 - EXHIBIT 10.22 - Salarius Pharmaceuticals, Inc.flks20151231ex-1022.htm
EX-10.21 - EXHIBIT 10.21 - Salarius Pharmaceuticals, Inc.flks20151231ex1021.htm
10-K - 10-K - Salarius Pharmaceuticals, Inc.flks2015123110-k.htm
EX-21.1 - EXHIBIT 21.1 - Salarius Pharmaceuticals, Inc.flks20151231ex-211.htm


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-201816) pertaining to the 2014 Equity Incentive Plan, 2015 Equity Incentive Plan, and 2015 Employee Stock Purchase Plan of Flex Pharma, Inc. of our report dated March 8, 2016, with respect to the consolidated financial statements of Flex Pharma, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2015.

 
 
/s/ Ernst & Young LLP
Boston, Massachusetts
 
 
March 8, 2016